Please verify

Blaze Media
Watch LIVE

Perino Responds to Dowd's Tongue-Lashing of GOP Mean Girls


"Two can play at that game, sister."

New York Times op-ed columnist Maureen Dowd used her space this Sunday to rail against "Republican Mean Girls." But to former White House Press Secretary Dana Perino, the uncomfortable rant was "stereotypical," "uncalled for," and "irritated me."

Dowd -- who may have been hurt by Republicans or attractive cheerleaders in the past -- compares X-only-chromosomed conservatives to "grown-up versions of those teenage tormentors who would steal your boyfriend, spray-paint your locker and, just for good measure, spread rumors that you were pregnant."

The leaders of the conservative female hit squad, she says, are Arizona Governor Jan Brewer, Nevada Senatorial candidate Sharron Angle, "Queen Bee" Sarah Palin, and Delaware's "sweet wannabee" Christine O'Donnell.

They have "replaced Hope with Spite and Cool with Cold," she writes, and "are the ideal nihilistic cheerleaders for an angry electorate."

Yet to Perino, the piece is nothing more than a "stereotypical and uncalled for" rant that lumps all Republican women into one simple category: mean. "Can women have moments they aren’t proud of?" Perino asks on NationalReviewOnline.com. "Sure. But to write all conservative and Republican women off as mean is . . . mean."

Channeling here best psychologist, Perino ponders the origins of Dowd's column:

Perhaps she was a mean girl. Or maybe mean girls picked on her. Not in high school, but in adulthood — and now she can think how powerful she is by writing catty columns on America’s most liberal editorial page.

Usually Perino would ignore such a piece. But in this busy mid-term election season when "most conservative women running for office don’t have time to stop and be petty," Perino can be. "I can do that for them."

"Two can play at that game, sister," she tells Dowd.

Maybe next week's column will be about mean former press secretaries.

Most recent

Elon Musk's Neuralink receives FDA green light for 'first-in-human clinical study'

All Articles